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Background: Acidosis is a major feature of progressive malnutrition in dialysis patients. Our previous study
showed that in peritoneal dialysis (PD) patients with mild acidosis, oral sodium bicarbonate improved nutritional
status and reduced hospitalization. However, the required duration of bicarbonate treatment remains unknown.
Methods: Patients who participated in our previously reported randomized, controlled study of sodium
bicarbonate therapy (J Am Soc Nephrol 2003;14:2119–26) were followed for another 12 months after treatment
was stopped. We compared the two groups (i.e. sodium bicarbonate therapy vs placebo) with regard to nutritional
status, including subjective global assessment (SGA) score and normalized protein nitrogen appearance (NPNA),
and hospitalization and mortality.
Results: In the treatment group, the overall SGA score tended to fall to the pretreatment level 12 months after
bicarbonate therapy was stopped (5.15 ( 1.04 to 4.68 ( 0.99, p = 0.08). After 12 months, there was no difference
in overall SGA score between the treatment and placebo groups (4.68 ( 0.99 vs 4.58 ( 1.10, p = 0.5). NPNA of
the treatment group remained marginally higher than that of the placebo group (1.21 ( 0.49 vs 1.06 ( 0.49 g/kg/day,
p = 0.21), although the difference was not statistically significant. There was no significant difference in the
duration of hospitalization between groups after bicarbonate was stopped (12.3 ( 19.9 vs 16.9 ( 23.7 days/year;
Kruskal-Wallis test, p = 0.31). The treatment group had a slightly higher actuarial patient survival (83.3% vs
76.7%; log-rank test, p = 0.22), but the difference was not statistically significant.
Conclusion: The therapeutic benefits of oral sodium bicarbonate disappeared rapidly when treatment was
stopped. Our results suggest that oral sodium bicarbonate is beneficial in PD patients with borderline dialysis
adequacy and mild metabolic acidosis, and that these patients require long-term bicarbonate treatment.
[Hong Kong J Nephrol 2005;7(1):14–21]
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INTRODUCTION
Acidosis, a classical feature of uremia, causes protein
catabolism mainly by the selective breakdown of
skeletal muscle protein [1]. However, the importance
of acidosis is often overlooked in dialysis patients.
When present, acidosis activates the ubiquitin-
proteasome machinery [2] and branched-chain keto-
acid dehydrogenase [3], resulting in catabolism of mus-
cle protein. Acidosis acts synergistically with other
catabolic factors, such as inflammatory cytokines and
insulin resistance, to induce protein catabolism [4].
There is ample laboratory evidence showing that
correction of acidosis prevents up-regulation of the
ubiquitin-proteasome machinery and reduces protein
degradation [5–9]. We recently reported a randomized,
placebo-controlled study that evaluated the effects of
correcting acidosis with oral sodium bicarbonate in
peritoneal dialysis (PD) patients with borderline dialy-
sis adequacy [10]. We found that bicarbonate sup-
plementation improved nutritional status, including
subjective global assessment (SGA) score for anorexia
and protein nitrogen appearance, and reduced the
duration of hospitalization.
However, the required duration of bicarbonate
therapy remains unclear. On the one hand, plasma
bicarbonate levels fall with time on PD because of a
progressive loss of residual renal function [11,12], and
long-term bicarbonate supplementation is predictably
needed. On the other hand, oral sodium bicarbonate
has potential problems: in our previous study, there was
a trend towards more hospital admissions for heart
failure and fluid overload in the treatment than placebo
group, although the difference was not statistically
significant [10]. Here, we report the outcomes for
participants in the abovementioned, randomized,
placebo-controlled trial, after the study medication was
stopped. Our objective was to determine whether the
therapeutic benefit of sodium bicarbonate supple-
mentation would disappear once the supplemen-
tation was stopped.
PATIENT AND METHODS
Original study protocol
The protocol of our original, randomized, controlled
trial has been described previously [10]. Briefly, we
randomized 60 PD patients who had acidosis and
dialysis adequacy (Kt/V) less than 2.1 to oral sodium
bicarbonate (0.9 g thrice daily) or placebo. Patients
were followed up for 12 months. In our original re-
port [10], we compared the groups with regard to the
following: nutritional status, including a 4-item 7-point
SGA score, normalized protein nitrogen appearance
(NPNA), fat-free edema-free body mass (FEBM),
serum albumin level, hospitalization, and all-cause
mortality.
Follow-up study protocol
After the 12 months of the initial study period, 49
patients remained alive and on PD. Their study
medications were stopped, but their other clinical
management was unaltered. The present report de-
scribes clinical outcomes for these patients after an
additional 12 months of follow-up.
Clearance studies and nutritional assessments were
performed immediately before, and 12 months after,
the study medication was stopped. As described pre-
viously [10], dialysis adequacy was determined by mea-
surement of total and peritoneal Kt/V [13]. Residual
glomerular filtration rate (GFR) was calculated from
the average of 24-hour urinary urea and creatinine
clearance [14]. Creatinine concentration in dialysate
was corrected for interference from glucose, according
to the reference formula determined in our laboratory
[15]. A 4-item 7-point system was used for SGA
assessment [16,17]. NPNA was calculated by the
modified Bergstrom’s formula [18] and normalized to
standard body weight (total body water/0.58). Total
body water (V) was determined by Watson’s formula
[19]. FEBM was determined from creatinine kinetics
according to Forbes and Bruining [20]. Serum albumin
level was measured by the bromcresol purple method.
The clinical outcomes in this study included
nutritional status, as described above, duration of
hospitalization resulting from all causes (normalized
to days per year of follow-up), and actuarial patient
survival. Transplantation and loss to follow-up were
censored observations in the calculation of actuarial
patient survival.
Statistical analysis
Statistical analysis was performed using SPSS version
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10.0 for Windows (SPSS Inc, Chicago, IL, USA). All
data are expressed as mean ( standard deviation (SD)
unless otherwise specified. A p value of less than 0.05
was considered statistically significant. All probabilities
were two-tailed. Analyses were intention to treat, ir-
respective of adherence to study regimens. Data be-
tween study groups were compared by the Chi-squared
test, Student’s t test, or Kruskal-Wallis test, as appropriate.
As described previously [10], the number and dura-
tion of hospital admissions were compared between
groups by analysis of covariance (ANCOVA). In this
analysis, hospitalization data were used as the de-
pendent variable (after correction for the duration of
follow-up, and log-transformation because the data
were highly skewed), treatment allocation was used as
the grouping factor, and the Charlson Comorbidity
Index was used as the covariate. Actuarial patient
survival was compared by log-rank test.
RESULTS
Demographic and clinical data
We enrolled 60 patients in our original study. Their
baseline demographic and clinical characteristics have
been described in our previous report [10] and are sum-
marized in Table 1. After the 12 months of the initial
study period, 49 patients (26 in the treatment group;
23 in the placebo group) remained alive and on PD.
Figure 1 shows the clinical trial profile.
Bicarbonate, dialysis adequacy and GFR
On completion of the initial study period, i.e. after 1
year of oral sodium bicarbonate, the treatment group
Table 1. Baseline demographic and clinical characteristics of the patients
Placebo group Treatment group
n 30 30
Sex (M:F) 19:11 16:14
Age (yr) 56.6 ( 13.2 54.3 ( 12.4
Duration of dialysis (mo) 39.4 ( 26.0 39.9 ( 20.8
Body height (m) 1.59 ( 0.07 1.61 ( 0.08
Body weight (kg) 63.2 ( 11.1 62.9 ( 8.7
Diagnosis (n)
   Glomerulonephritis 11 11
   Diabetes 8 12
   Polycystic 3 0
   Obstruction 2 2
   Others/unknown 6 5
Major comorbidity (n)
   Diabetes 9 12
   Cardiovascular disease 14 14
   Charlson Comorbidity Index score 4.8 ( 1.8 5.3 ( 2.0
Figure 1. Clinical trial profile. HD = hemodialysis.
had a significantly higher plasma bicarbonate level than
the control group (24.9 ( 2.6 vs 22.9 ( 3.1 mmol/L;
p = 0.015). After sodium bicarbonate was stopped,
plasma bicarbonate level in the treatment group
declined from 24.9 ( 2.6 to 22.7 ( 3.1 mmol/L (p =
0.003); there was an insignificant drop in plasma
60 randomized
30 assigned NaHCO3 30 assigned placebo
4 did not
tolerate study
drug
3 did not
tolerate study
drug
2 died
1 converted to HD
1 transplant
5 died
1 converted to HD
1 transplant
3 died
1 converted to HD
2 transplant
2 died
1 converted to HD
26 followed-up at 1 year 23 followed-up at 1 year
20 followed-up at 2 years 20 followed-up at 2 years
Hong Kong J Nephrol • April 2005 • Vol 7 • No 1 17
Acidosis in CAPD
bicarbonate level in the control group (22.9 ( 3.1 to
22.5 ( 3.5 mmol/L; p = 0.5). Indices of dialysis ade-
quacy and residual GFR over the study period are shown
in Table 2.
Nutritional status
The indices of nutritional status are summarized in
Figure 2. Overall SGA score increased from 4.30 (
0.88 to 5.15 ( 1.04 (p < 0.001) in the treatment group
after 12 months of bicarbonate treatment, but fell to
the pretreatment level 12 months after bicarbonate
therapy was stopped (5.15 ( 1.04 to 4.68 ( 0.99; p =
0.08). In the placebo group, overall SGA score remained
static over the 2-year study period (Figure 2A). After
bicarbonate therapy had been stopped for 12 months,
there was no difference in overall SGA score between
the treatment and placebo groups (4.68 ( 0.99 vs 4.58 (
1.10; p = 0.5). When the 4-item SGA scores were
analyzed, similar trends were observed for all items,
although only score changes for anorexia and weight
loss were statistically significant (details not shown).
NPNA increased marginally from 1.17 ( 0.33 to
1.28 ( 0.27 g/kg/day in the treatment group after 12
months of bicarbonate treatment, but this change was
not statistically significant (p = 0.16). However, NPNA
tended to fall to the pretreatment level 12 months after
bicarbonate therapy was stopped (1.28 ( 0.27 to 1.21 (
0.49 g/kg/day; p = 0.4). In the placebo group, NPNA
declined insignificantly from 1.13 ( 0.27 to 1.03 (
0.27 g/kg/day (p = 0.15) during the first year of the
study period, and remained low during the second year
(Figure 2B). After bicarbonate therapy had been stopped
for 12 months, NPNA in the treatment group remained
marginally higher than in the placebo group (1.21 (
0.49 vs 1.06 ( 0.49 g/kg/day), but the difference was
not statistically significant (p = 0.21).
FEBM rose insignificantly from 30.8 ( 8.2 to 33.4 (
8.8 kg (p = 0.23) in the treatment group after 12 months
of bicarbonate treatment, and remained static 12 months
after bicarbonate therapy was stopped (33.4 ( 8.8 to
33.9 ( 8.1 kg; p = 0.5). In the placebo group, FEBM
remained static over the 2-year study period (Figure
2C). After bicarbonate therapy had been stopped for
12 months, FEBM in the treatment group remained
marginally higher than in the placebo group (33.9 (
8.1 vs 31.1 ( 6.3 kg), but the difference was not statisti-
cally significant (p = 0.13).
Serum albumin level remained static in both groups
over the 2-year study period (Figure 2D). There was
no appreciable difference in serum albumin level
between the groups at any time point.
Hospitalization
There was no significant difference in the duration of
hospitalization between the groups 12 months before
enrollment into the study (12.1 ( 15.8 vs 13.1 ( 18.5
days/year; Kruskal-Wallis test, p = 0.9; Figure 3).
During the initial 12 months of the study period, there
were a total of 53 hospital admissions in the treatment
group; the total duration of hospital stay was 253 days.
In the placebo group, there were 73 hospital admissions,
with a total duration of 504 days. As summarized in
Figure 3, the treatment group had a significantly short-
er hospital stay than the placebo group (8.4 ( 17.7 vs
16.8 ( 21.7 days/year; Kruskal-Wallis test, p = 0.044).
During the 12 months after bicarbonate therapy was
stopped, there were a total of 57 hospital admissions in
the treatment group; the total duration of hospital stay
was 296 days. In the placebo group, there were 77
hospital admissions, with a total duration of 440 days.
There was no significant difference in the duration of
hospitalization between the two groups (12.3 ( 19.9 vs
16.9 ( 23.7 days/year; Kruskal-Wallis test, p = 0.31;
Figure 3).
As described in our previous report [10], during the
12 months of bicarbonate therapy, we noted that patients
in the treatment group were marginally more likely to
require admission for fluid overload than patients in
Table 2. Dialysis adequacy and residual renal function*
Baseline 12 months 24 months
Total Kt/V
   Treatment group 1.91 ( 0.52 1.77 ( 0.31 1.76 ( 0.18
   Placebo group 1.93 ( 0.51 1.78 ( 0.30 1.73 ( 0.29
Peritoneal Kt/V
   Treatment group 1.56 ( 0.39 1.69 ( 0.32 1.69 ( 0.26
   Placebo group 1.57 ( 0.35 1.59 ( 0.36 1.61 ( 0.31
Residual GFR (mL/min)
   Treatment group 1.78 ( 2.36 0.81 ( 1.04 0.44 ( 1.02
   Placebo group 1.91 ( 2.65 0.68 ( 1.04 0.65 ( 1.21
*There were no statistically significant differences between groups at any time point. GFR = glomerular filtration rate.
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the placebo group (112 vs 89 days of hospitalization),
but the difference was not statistically significant (p =
0.36). There was no difference in the duration of
hospitalization for fluid overload between the two
groups during the 12 months after bicarbonate therapy
was stopped (92 vs 84 days; p = 0.9).
Mortality and technique failure
During the 24 months of the study period, five patients
in the treatment group died from myocardial infarction
(n = 2), peritonitis (n = 1), non-peritonitis infection
(n = 1), and malignancy (n = 1). Seven patients in the
placebo group died from myocardial infarction (n = 3),
peritonitis (n = 2), mesenteric infarction (n = 1), and
peripheral vascular disease (n = 1). Two patients from
each group were transferred to long-term hemodialysis;
and three from the treatment group and one from the
placebo group underwent kidney transplantation.
Kaplan-Meier survival curves are shown in Figure 4.
At 24 months, the treatment group had slightly higher
actuarial patient survival (83.3% vs 76.7%), but the
difference was not statistically significant (log-rank
test, p = 0.22).
DISCUSSION
During the past decade, systemic acidosis has in-
creasingly been recognized as a cause of malnutrition.
Systemic acidosis increases protein degradation and
amino acid oxidation [21,22]. Further, in the presence
of systemic acidosis, there is a preferential loss of
Figure 2. Indices of nutritional status in the treatment group (white circles) and placebo group (black circles): (A) overall subjective
global assessment (SGA) score; (B) normalized protein nitrogen appearance (NPNA); (C) fat-free edema-free body mass (FEBM); and
(D) serum albumin level. Error bars denote standard error of mean.
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protein from skeletal muscle, particularly from pale
muscle fibers that are used intermittently, while visceral
organs (e.g. the kidneys and liver) lose little protein
and the brain is relatively spared [1,23]. The pathways
responsible for accelerated proteolysis in acidosis
have been identified as the adenosine-triphosphate-
dependent ubiquitin-proteasome system [1,2] and the
enzyme branched-chain ketoacid dehydrogenase [3].
Acidosis also acts synergistically with other catabolic
factors [1].
In uremic rats with acidosis, correction of acidosis
not only reduced proteolysis, but also prevented an
increase in mRNAs for ubiquitin and proteasome
subunits [5]. Human studies confirm that nitrogen
balance improves when the acidosis associated with
chronic renal insufficiency is corrected [6–9]. Using a
continuous L-[1-13C]leucine infusion technique, Reaich
et al found that sodium bicarbonate treatment in pre-
dialysis renal failure patients led to a significant re-
duction in leucine appearance (representing protein
degradation), leucine disappearance into body protein
(representing protein synthesis), and leucine oxidation
[6]. Similar results were subsequently observed in
hemodialysis patients [7] and PD patients [8,9].
Several investigators prospectively evaluated the
effects of correcting metabolic acidosis on nutritional
status in dialysis patients [24–29]. Overall, the bene-
ficial effects were inconsistent and usually limited,
but there were two major reasons for this finding [30].
First, the sample size in most studies was small,
such that the trials had inadequate power to detect an
improvement in nutritional status. Second, many pa-
tients studied had either normal or only mildly im-
paired nutritional status.
To date, there are four published randomized, con-
trolled trials about the correction of acidosis in end-
stage renal failure patients: two studies in hemodialysis
patients [31,32] and two in PD patients [10,33]. Results
from these trials are summarized in Table 3. Williams
et al examined 46 stable hemodialysis patients using
low-concentration (30 mmol/L) or high-concentration
(40 mmol/L) bicarbonate dialysate in a single-blind,
double-crossover study of two consecutive 6-month
periods [31]. With high-concentration bicarbonate di-
alysate, triceps skinfold thickness showed a signifi-
cant increase. However, the change was rapidly re-
versed after changing the dialysate bicarbonate con-
centration. No differences in mid-upper arm circum-
ference, urea generation rate or NPNA were found.
Brady and Hasbargen randomized 36 hemodialysis
patients to either a standard-concentration (35 mmol/L)
or high-concentration (40 mmol/L) bicarbonate
dialysate [32]. Although the plasma bicarbonate level
was significantly different, there was no difference in
serum albumin level or total lymphocyte count between
the two groups.
Stein et al randomized 200 new PD patients, in
single-blind fashion, to receive a high-concentration
(40 mmol/L) or low-concentration (35 mmol/L) lactate
dialysate for 1 year [33]. Patients treated with high-
concentration lactate had a greater increase in mid-
arm circumference, but more importantly, a shorter du-
ration of hospitalization. We performed a randomized,
placebo-controlled study in 60 PD patients with acido-
sis and borderline dialysis adequacy [10]. Bicarbonate
therapy significantly improved overall SGA score and
dietary protein intake. There was also a significant
reduction in the duration of hospitalization in the
Figure 3. Duration of hospitalization in the treatment and placebo
groups: (A) 12 months before enrollment into the study; (B) during
the 12 months of treatment; and (C) 12 months after study
medication was stopped. Data are illustrated by the Whisker-box
plot, with boxes indicating median values, and the 25th and 75th
percentiles; whisker caps indicating the 5th and 95th percentiles;
and open circles indicating outliers. P = placebo group; T =
treatment group.
Figure 4. Kaplan-Meier survival estimates for the treatment and
placebo groups.
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treatment group. Thus, overall, published clinical trials
suggest that correction of metabolic acidosis in dialysis
patients can improve nutritional status and probably
reduce hospitalization. The benefit is apparently great-
er in PD than hemodialysis patients, which may be
explained by the larger sample sizes in the two trials in
PD patients [10,33].
In the present study, the beneficial effects of oral
sodium bicarbonate quickly disappeared once treat-
ment was stopped. Overall SGA score, which was the
most important index of malnutrition, declined to
pretreatment levels within 1 year, and the duration of
hospitalization increased. Further, Kaplan-Meier
survival plots show that actuarial survival in the
treatment group declined rapidly about 9 months after
bicarbonate therapy was stopped (Figure 4), thus im-
plying loss of effect after previously improved nu-
tritional status. Although NPNA and FEBM seemed
to be maintained after bicarbonate treatment was
stopped (Figures 2B and 2C), overall changes in these
measures during the study period were small; in ad-
dition, the possibility of a confounding effect could
not be excluded because these two parameters were
mathematically coupled with Kt/V and weekly cre-
atinine clearance, and all of these parameters were
measured and calculated from the same 24-hour urine
and dialysate collection [34].
It might be argued that it was unethical to stop
sodium bicarbonate in our patients because definite
therapeutic benefit was observed in our original study
[10]. However, the optimal duration of alkali supple-
mentation has not yet been defined, and most pub-
lished studies have been short-term. As sodium bi-
carbonate supplementation has some problems (e.g.
hospitalization for fluid overload was slightly more
common in the treatment than placebo group in our
original report), we decided to stop the study medica-
tion and observe whether there was any lasting effect
of treatment.
Our data have two implications. First, they further
support the beneficial effects of bicarbonate therapy.
Interestingly, the treatment group required marginally
more hospitalization for fluid overload than the placebo
group during the 12 months of treatment [10], although
the difference disappeared in the subsequent year (i.e.
after bicarbonate was stopped). It seems highly probable
that such increased hospitalization resulted from an
excessive oral sodium load rather than from a chance
finding. Second, our data imply that the treatment of
metabolic acidosis in dialysis patients should be long
term because the treatment effect is of short duration.
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Table 3. Randomized, controlled trials evaluating the response of metabolic acidosis to treatment in dialysis patients
Authors (year) [reference] Number of Duration of Key findings Commentspatients treatment (mo)
Williams et al (1997) [31] 46 6 Increased triceps skinfold Only 34 patients completed the
thickness; no change in study; double-crossover design;
serum albumin, NPNA, change in triceps skinfold thickness
or mid-arm circumference was rapidly reversed after switching
treatment; muscle build did not
improve
Brady & Hasbargen 36 4 No change in serum albumin Muscle mass was not assessed
(1998) [32] or lymphocyte count
Stein et al (1997) [33] 200 12 Increase in mid-arm circum- High dropout rate (around 60%);
ference; no change in dietary “treatment arm” in this study
protein intake, serum albumin (lactate 40 mmol/L) is actually the
and triceps skinfold thickness; standard treatment in many
reduced hospitalization countries
Szeto et al (2003) [10] 60 12 Increase in SGA score and Beneficial effect largely via
NPNA; no change in serum improved appetite; apparently no
albumin; reduced hospitali- change in protein degradation
zation
NPNA = normalized protein nitrogen appearance; SGA = subjective global assessment.
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